收购详情 - 完成了对RayzeBio, Inc.的收购，RayzeBio现在是Bristol Myers Squibb的全资子公司[1] - Bristol Myers Squibb通过并购RayzeBio，加强了其肿瘤学管道，拓展了放射性药物治疗的新领域[2] - Bristol Myers Squibb以每股62.50美元的现金价格收购了RayzeBio的所有流通股份，总价约为41亿美元[3] 股东咨询 - RayzeBio的股东可以向信息代理Georgeson LLC咨询有关收购要约的问题[6] 顾问信息 - Bristol Myers Squibb的财务顾问是BofA Securities, Inc.，法律顾问是Covington & Burling LLP[7] 公司背景 - Bristol Myers Squibb是一家全球生物制药公司，致力于发现、开发和提供帮助患者战胜严重疾病的创新药物[8] 风险提示 - 本次收购存在一定的风险和不确定性，包括收购预期的好处未能实现、与收购协议相关的法律诉讼风险等[11]

Here are three stocks added to the Zacks Rank #5 (Strong Sell) List today:Blackstone Mortgage Trust, Inc. (BXMT) is a real estate finance company. The Zacks Consensus Estimate for its current year earnings has been revised 11.6% downward over the last 60 days.Bristol-Myers Squibb Company (BMY) is a biopharmaceutical company. The Zacks Consensus Estimate for its current year earnings has been revised 8.5% downward over the last 60 days.Clearway Energy, Inc. (CWEN) is a renewable energy company.The Zacks Cons ...

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today announced that its previously announced tender offer (the “Offer”) to acquire all of the outstanding shares of RayzeBio, Inc. (Nasdaq: RYZB) common stock for a purchase price of $62.50 per share in cash, or approximately $4.1 billion, expired at one minute after 11:59 p.m., Eastern Time, on February 22, 2024 (the “Expiration Time”). Equiniti Trust Company, the depositary for the Offer, has advised that, as of the Expiration Time, appr ...

产品治疗适应症 - Bristol Myers宣布FDA已接受其补充新药申请（sNDA）用于Krazati与Erbitux联合治疗先前接受治疗的KRAS突变局部晚期或转移性结直肠癌（CRC）[1] - sNDA提交寻求批准Krazati/Erbitux联合疗法治疗CRC适应症，基于Bristol Myers的KRYSTAL-1研究的积极结果[5] 批准情况 - Krazati最初于2022年获得批准，用于治疗KRAS突变的成年患者局部晚期或转移性非小细胞肺癌（NSCLC），该批准是在FDA的加速批准途径下获得的，继续批准此适应症取决于Bristol Myers对Krazati的确证研究的成功[3] - 公司还获得了欧盟对Krazati作为针对KRAS突变晚期NSCLC患者的有条件上市授权，该患者在至少接受一种先前系统疗法后疾病进展[4] 临床研究 - KRYSTAL-1研究的注册阶段II队列的主要终点是客观反应率，次要终点包括反应持续时间、无进展生存期、总生存期和安全性[6] - 根据KRYSTAL-1研究的数据，观察到Krazati在KRAS突变的la/m CRC患者中耐受良好，并提供了有前途的临床活性，与Erbitux联合使用表现出一致的安全性[7] 其他信息 - 提醒投资者，Krazati是在2024年1月完成对Mirati Therapeutics的48亿美元收购后添加到Bristol Myers的肿瘤学组合中的[8] - Bristol Myers继续评估Krazati作为单药治疗和与其他抗癌疗法联合治疗的患有先进KRAS突变实体瘤的患者，包括NSCLC和CRC[9]

Bristol Myers Squibb第四季度业绩 - 宾夕法尼亚州费城举行的2023年宾夕法尼亚妇女大会上，Bristol Myers Squibb报告了其第四季度业绩，收入和盈利超过了市场预期[1] - Bristol Myers Squibb在第四季度的营收为115亿美元，同比增长1%，但Revlimid的销售下降影响了整体营收增长[6] BMY股票表现 - BMY股票自2021年初的60美元水平下跌了15%，目前约为50美元，表现不佳[3] - BMY股票的估值展望较好，预计可达到65美元每股，相比目前的50美元有约30%的上涨空间[5] Bristol Myers Squibb财务状况 - Bristol Myers Squibb的调整毛利率在第四季度同比下降150个基点至76.4%，部分原因是产品组合[7] - 尽管Bristol Myers Squibb面临短期挑战，但其长期增长前景看好，新药预计将在未来几年成为畅销药品[8]

Picking the best stocks for beginning investors is crucial as they enter the world of long-term investing. With a myriad of options available, it’s essential to focus on stocks that offer growth potential and stability. Despite the short-term market volatility, investing in stocks remains one of the most reliable ways to build wealth over time.In this article, we’ll introduce three stocks for beginning investors that deserve your attention in February 2024. They not only provide a solid foundation for your ...

公司债券发行 - 布里斯托尔-迈尔斯-斯奎布公司宣布发行总额为130亿美元的无担保债券[1] - 发行的债券将分为九个档次，分别在不同年限内到期[1] - 预计发行将于2024年2月22日结束[2] - 公司计划将募集资金的一部分用于收购Karuna Therapeutics, Inc.和RayzeBio, Inc.[3] - 若收购Karuna Therapeutics, Inc.未在2025年6月30日前完成，公司将被要求赎回所有未偿还的债券[3] - Citigroup Global Markets Inc.、BofA Securities, Inc.、Wells Fargo Securities, LLC和Mizuho Securities USA LLC将担任发行的联合主承销商和联合簿记管理人[4] - 债券发行是根据有效的注册声明进行的[5] 公司背景介绍 - 布里斯托尔-迈尔斯-斯奎布公司是一家全球生物制药公司，致力于发现、开发和提供帮助患者战胜严重疾病的创新药物[10] 风险和不确定性提醒 - 公司提醒投资者关于前瞻性声明的注意事项，包括风险和不确定性[7] - 前瞻性声明应与影响公司业务和市场的风险和不确定性一起评估[9]

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today announced that it recently became aware of an unsolicited “mini-tender” offer by Tutanota LLC (“Tutanota”) to purchase up to five hundred thousand shares of Bristol Myers Squibb’s common stock, representing significantly less than one percent of Bristol Myers Squibb’s common stock outstanding, at an offer price of $55 per share (“Offer Price”). The offer is conditioned on, among other things, the closing price per share of Bristol Mye ...

PALM BEACH, Fla., Feb. 14, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - Recent reports project that the anal cancer market will continue its recent growth through 2030. An article on the MD Anderson website. It said: "More than 8,000 people in the U.S. are diagnosed with anal cancer each year. Due to higher rates of the human papilloma virus, a key risk factor, it affects women more than men. If found early, the disease can be successfully treated. Several types of tumors may be found in the an ...

NEW YORK--(BUSINESS WIRE)--VantAI, a company focused on generative AI-enabled drug discovery, and Bristol Myers Squibb (NYSE: BMY), a leading pharmaceutical company, have entered into a strategic collaboration to discover new molecular glues for therapeutic targets of interest. The partnership leverages VantAI's geometric deep learning capabilities with Bristol Myers Squibb’s expertise in targeted protein degradation to discover and develop new small molecule therapeutics. The collaboration will focus on ...